The prognostic ability of PGG for multiple long term clinical endpoints was examined using Cox models. Interactions between PGG and race were tested.
INTRODUCTION AND OBJECTIVES:
Comorbidities are medical disorders co-existing in patients with prostate cancer (PCa). Comorbidity, like PCa, is age-related and prevalent, influencing treatment choices. Although comorbidity may adversely affect competing-cause mortality in PCa patients, the impact on PCa-specific mortality is not known.
METHODS: Using the PcBaSe Sweden composite population-based dataset, 118543 men diagnosed with PCa between 1998 and 2012, and followed up for survival until 2014 were identified. Median follow-up was 8.3 (IQR¼5.2-11.5) years to death from PCa or other causes. Patients were categorised by patient (marital status, educational level) RESULTS: In the complete unadjusted dataset, an effect of increasing comorbidity was observed on PCa-specific and othercause mortality. Following adjustments for patient and tumour characteristics, the effect of comorbidity on PCa-specific mortality was lost, while maintained for other-cause mortality. Following additional adjustment for treatment type, an effect of comorbidity on PCaspecific mortality was not observed, while present for other-cause mortality.
CONCLUSIONS: During the study period in Sweden, comorbidity appeared to affect other-cause, but not PCa-specific, mortality after accounting for patient and tumour characteristics, and treatment type. Increasing comorbidity did not impact on PCa-specific mortality irrespective of radical treatment (RP or RT). Consequently, in population-based comparative PCa treatment effectiveness studies, the differences in oncological outcomes may not be due to the varying distribution of comorbidity among treatment groups, hence comorbidity is unlikely to be a confounder.
Source of Funding: None; PcBaSe Sweden is funded by the Swedish Research Council (25-2012-5047).
PD03-12 PROSTATE CANCER INCIDENCE STRATIFIED BY RACE AND GLEASON SCORE: A SEER DATABASE ANALYSIS OF THE USPSTF GUIDELINE ERA
Daniel Au*, Johar Syed, Sameer Siddiqui, Saint Louis, MO INTRODUCTION AND OBJECTIVES: In 2008 and extended in 2012, the US Preventive Services Task Force (USPSTF) issued guidelines stating there was insufficient evidence to support prostate cancer screening. Using the Surveillance Epidemiology and End Result (SEER) database, we sought to determine the effect of recent USPSTF recommendations on prostate cancer incidence based on Gleason score (GS), and to identify differences in GS based on race.
METHODS: SEER database was analyzed from 2008-2013. Patients were divided based on recorded race. GS were stratified as low (2-6), intermediate (7) or high (8-10). Incidence was compared between 2008 and 2013 by determining incidence rate ratio (IRR) and annual percentage change (APC). Statistical analysis was performed with SEERSTAT and excel, confidence interval was set at 95%, with p< 0.05 as significant. RESULTS: 337,504 patients diagnosed with prostate cancer within SEER 18 between 2008 and 2013 were included in the analysis. The mean age range was between 65-74 years. Majority (68.1%) of patients were White, followed by 14.6% Black. GS 2-6 was recorded for 41.8%, followed by GS 7 in 36.2% of patients, and GS 8-10 in 15.9% of patients. Cumulative six year GS 2-6 incidence was noted to be 76.2, 52.9, 44.7 and 25.0 per 100,000 for Black (B), White (W), Hispanic (H), and Asian/Pacific Islanders (API), respectively. GS 7 incidences were 81.3, 46.4, 36.2 and 23.4 per 100,000 for B, W, H, and API, respectively. GS 8-10 was reported in 37.5, 21.0, 21.7 and 18.0 per 100,000 for B, W, H, and API, respectively. The IRR demonstrated a decline in incidence across races and Gleason scores. Between 2008 and 2013 GS 7 IRRs were 0.74 B, 0.65 W, 0.61 H, 0.60 API and GS 8-10 IRRs were 0.85 B, 0.89 W, 0.83 H, 0.78 API. APC significantly declined among all races for GS 2-6 (-8.56 B, -8.87 W, -8.63 H and -8.68 API) and GS 7 (-6.54 B, -8.56 W, -9.23 H and -9.91 API). Additionally, APC significantly declined for B and H GS 8-10 (-3.51 B, -4.39 H). APC of GS 8-10 incidence showed no statistically significant increase or decline for W and API (-2.28 W, -5.05 API).
CONCLUSIONS: Analysis of SEER demonstrates a decline in incidence of prostate cancer among all races. Notably, there was a decline in GS 8-10 prostate cancer incidence for B, W, H, and API groups, suggesting reduced diagnosis of aggressive prostate cancer in the USPSTF guideline era. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e61
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DETERMINANTS OF ALL-CAUSE MORTALITY IN PATIENTS WITH METASTATIC PAPILLARY RENAL CELL CANCER
Abhinav Sidana*, Amit Jain, Meet Kadakia, Akhil Muthigi, Louis Krane, Martha Ninos, Julia Friend, Johanna Shih, Ramaprasad Srinivasan, Bethesda, MD INTRODUCTION AND OBJECTIVES: While prognostic factors determining survival in metastatic clear cell renal cell cancer patients are well established, little is known about predictors of outcome in metastatic papillary renal cell cancer (pRCC) patients. We aim to determine the predictors of all-cause mortality (ACM) in pRCC patients.
METHODS: Retrospective evaluation of the medical records of patients with metastatic pRCC seen at National Cancer Institute (2000-2014) was undertaken. Patient demographics, tumor characteristics and outcomes were studied. Kaplan-Meier Survival analysis was done to estimate overall survival (OS). Multivariate Cox proportional-hazards regression analysis was done to identify predictors of ACM.
RESULTS: 106 consecutive patients with metastatic pRCC were identified. The median age and follow up time after the diagnosis of metastases was 50 years (11-80) and 33.8 mon (2.3-246.7) respectively. Twenty-one (19.8%) and 42 (39.6%) patients had papillary type 1 and papillary type 2 renal cancers respectively; in 43 (40.5%) patients, tumors were classified as papillary, not otherwise specified. Half (53) of patients had hereditary origin of pRCC. Median estimated OS of the entire cohort was 37.5 mon. There was no difference in survival between patients with hereditary or sporadic pRCC (p¼0.80) or among patients with different subtypes of pRCC (p¼0.79). On univariate analysis, elevated serum corrected calcium, elevated lactate dehydrogenase, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio and presence of malignant ascites significantly affected the patients 0 prognosis. Corrected Calcium (p¼0.03) and NLR (p¼0.004) were found to be independent predictors of ACM on multivariate analysis.
CONCLUSIONS: To our knowledge, this is the largest single center series evaluating survival and predictors of ACM within patients with metastatic pRCC. OS was comparable between different subtypes of metastatic pRCC. Elevated NLR and serum corrected calcium are significantly associated with worse OS. Future validation in larger multi-institutional cohorts could justify incorporating corrected calcium and NLR in nomograms predicting ACM in metastatic pRCC.
Source of Funding: Intramural research program at National Institutes of Health PD04-02
